Comparison of Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot and CMV Quantiferon Gamma Interferon-Releasing Assays in Assessing Risk of CMV Infection in Kidney Transplant Recipients

AUTHOR CORRECTION

Volume 51, no. 8, p. 2501–2507, 2013. Page 2502, Materials and Methods, “Patients and definitions” section, line 2: “125 kidney transplant recipients” should read “120 kidney transplant recipients.”

Page 2502, Materials and Methods, “Patients and definitions” section, line 7: “One hundred twenty-five KTRs” should read “One hundred twenty KTRs.”

Page 2502, Materials and Methods, “Patients and definitions” section: Information about the transplant immunosuppression induction protocol used was inadvertently omitted. The following statement should be inserted at the end of line 9: “The following induction immunosuppressive treatments were employed: antithymocyte globulin (ATG) for 67/120 patients (56%) (median age of cohort, 60 years), basiliximab for 47/120 patients (39%) (median age of cohort, 48 years), both ATG and basiliximab for 3/120 patients (2.5%) (median age of cohort, 34 years), and alefacept for 3/120 patients (2.5%) (median age of cohort, 33 years).” The overall results and conclusions of the study are unchanged.